Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel STAT3 inhibitor affects DLBCL growth

Key clinical point: Napabucasin, a novel inhibitor of STAT3, inhibits growth and shows synergy with doxorubicin in DLBCL.

Major finding: Napabucasin exhibited potent cytotoxicity on DLBCL xenograft tumors without obvious drug toxicity in vivo.

Study details: A panel of cell lines were treated with napabucasin and assessed for growth, viability.

Disclosures: The authors declared that they had no conflicts of interest.

Citation:

Li X et al. Cancer Letters. 2020; doi.org/10.1016/j.canlet.2020.07.032.